JP2022505597A5 - - Google Patents
Info
- Publication number
- JP2022505597A5 JP2022505597A5 JP2021521995A JP2021521995A JP2022505597A5 JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5 JP 2021521995 A JP2021521995 A JP 2021521995A JP 2021521995 A JP2021521995 A JP 2021521995A JP 2022505597 A5 JP2022505597 A5 JP 2022505597A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- salt according
- fluorine atoms
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862750395P | 2018-10-25 | 2018-10-25 | |
| US62/750,395 | 2018-10-25 | ||
| PCT/IB2019/059004 WO2020084480A1 (en) | 2018-10-25 | 2019-10-22 | Inhibitors of human immunodeficiency virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505597A JP2022505597A (ja) | 2022-01-14 |
| JP2022505597A5 true JP2022505597A5 (cg-RX-API-DMAC7.html) | 2022-10-11 |
| JP7500555B2 JP7500555B2 (ja) | 2024-06-17 |
Family
ID=68344929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521995A Active JP7500555B2 (ja) | 2018-10-25 | 2019-10-22 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210393633A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3870575B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7500555B2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2942998T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3870575T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020084480A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| MA53973A (fr) | 2018-10-24 | 2022-02-09 | Viiv Healthcare Uk No 5 Ltd | Inhibiteurs de la réplication du virus de l'immunodéficience humaine |
| WO2020084491A1 (en) * | 2018-10-24 | 2020-04-30 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| ES2969030T3 (es) * | 2018-10-29 | 2024-05-16 | Viiv Healthcare Uk No 5 Ltd | Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana |
| US20220211704A1 (en) * | 2019-04-30 | 2022-07-07 | Viiv Healthcare Uk (No. 5) Limited | Inhibitors of human immunodeficiency virus replication |
| IL291436B1 (en) * | 2019-09-20 | 2026-07-01 | Ideaya Biosciences Inc | History of indole and indazole sulfonamido 4-mutates as PARG inhibitors |
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Viiv醫療保健英國(No 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2021070054A1 (en) * | 2019-10-08 | 2021-04-15 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US12564595B2 (en) | 2019-11-28 | 2026-03-03 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於hiv之治療性化合物 |
| AR132951A1 (es) | 2023-06-15 | 2025-08-13 | Viiv Healthcare Uk No 5 Ltd | Métodos e intermedios para preparar compuestos |
| WO2025169059A1 (en) | 2024-02-05 | 2025-08-14 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| CA2840095A1 (en) | 2011-07-06 | 2013-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| EP2943493B1 (en) | 2013-01-09 | 2017-08-02 | Gilead Sciences, Inc. | Therapeutic compounds for the treatment of viral infections |
| TW201443037A (zh) * | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) * | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| WO2015130964A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Therapeutic compounds |
| US9873680B2 (en) | 2014-08-29 | 2018-01-23 | Gilead Sciences, Inc. | Therapeutic compounds |
| LT3347352T (lt) | 2016-08-19 | 2019-08-12 | Gilead Sciences, Inc. | Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| WO2019161017A1 (en) | 2018-02-15 | 2019-08-22 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| KR102847339B1 (ko) | 2018-02-16 | 2025-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체 |
| WO2019198024A1 (en) * | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| JP2022506399A (ja) * | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
-
2019
- 2019-10-22 PT PT197946791T patent/PT3870575T/pt unknown
- 2019-10-22 JP JP2021521995A patent/JP7500555B2/ja active Active
- 2019-10-22 US US17/284,855 patent/US20210393633A1/en not_active Abandoned
- 2019-10-22 EP EP19794679.1A patent/EP3870575B1/en active Active
- 2019-10-22 WO PCT/IB2019/059004 patent/WO2020084480A1/en not_active Ceased
- 2019-10-22 ES ES19794679T patent/ES2942998T3/es active Active